eNOS gene transfer inhibits smooth muscle cell migration and MMP-2 and MMP-9 activity

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 19, Issue 12, 1999, Pages 2871-2877

  Gurjar, Milind V ^a   Sharma, Ram V ^a   Bhalla, Ramesh C ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Cell migration; Endothelial nitric oxide synthase; Gene transfer; Matrix metalloproteinases; Smooth muscle cells; Tissue inhibitor of metalloproteinases

Indexed keywords

GELATINASE A; GELATINASE B; NITRIC OXIDE SYNTHASE; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ANIMAL CELL; ARTICLE; CELL MIGRATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; GENE TRANSFER; GUINEA PIG; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SMOOTH MUSCLE FIBER;

EID: 0033387969     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.19.12.2871     Document Type: Article

References (44)

1. Pauletto P, Sartore S, Pessina AC. Smooth-muscle-cell proliferation and differentiation in neointima formation and vascular restenosis. Clin Sci. 1994;87:467-479.
2. Casscells W. Migration of smooth muscle and endothelial cells: critical events in restenosis. Circulation. 1992;86:723-729.
3. Nabel EG, Nabel GJ. Prospects for gene therapy in cardiovascular diseases. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology Diagnosis Management. 2nd ed. New York, NY: Raven Press Ltd; 1995;3137-3149.
4. Matrisian LM. The matrix-degrading metalloproteinases. Bioessays. 1992; 14:455-463.
5. Dollery CM, McEwan JR, Henney AM. Matrix metalloproteinases and cardiovascular disease. Circ Res. 1995;77:863-868.
6. Pauly RR, Passaniti A, Bilato C, Monticone R, Cheng L, Papadopoulos N, Gluzband YA, Smith L, Weinstein C, Lakatta EG, Crow MT. Migration of cultured vascular smooth muscle cells through a basement membrane barrier requires type IV collagenase activity and is inhibited by cellular differentiation. Circ Res. 1994;75:41-54.
7. George SJ, Zaltsman AB, Newby AC. Surgical preparative injury and neointima formation increase MMP-9 expression and MMP-2 activation in human saphenous vein. Cardiovasc Res. 1997;33:447-459.
8. Galis ZS, Muszynski M, Sukhova GS, Simon-Morrissey E, Unemori EN, Lark MW, Amento E, Libby P. Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circ Res. 1994;75:181-189.
9. Zempo N, Kenagy RD, Au YPT, Bendeck M, Clowes MM, Reidy MA, Clowes AW. Matrix metalloproteinases of vascular wall cells are increased in balloon-injured rat carotid artery. J Vasc Surg. 1994;20:209-217.
10. Forough R, Koyama N, Hasenstab D, Lea HJ, Clowes MM, Nikkari ST, Clowes AW. Overexpression of tissue inhibitor of matrix metalloproteinase-1 inhibits vascular smooth muscle cell functions in vitro and in vivo. Circ Res. 1996;79:812-820.
11. Zempo N, Koyama N, Kenagy RD, Lea HJ, Clowes AW. Regulation of vascular smooth muscle cell migration and proliferation in vitro and in injured rat arteries by a synthetic matrix metalloproteinase inhibitor. Arterioscler Thromb. 1996;16:28-33.
12. Rubanyi GM. The role of endothelium in cardiovascular homeostasis and diseases. J Cardiovasc Pharmacol. 1993;22(suppl 4):S1-S14.
13. Scott-Burden T, Vanhoutte PM. Regulation of smooth muscle cell growth by endothelium-derived factors. Tex Heart Inst J. 1994;21:91-97.
14. Sarkar R, Meinberg EG, Stanley JC, Gordon D, Webb RC. Nitric oxide reversibly inhibits the migration of cultured vascular smooth muscle cells. Circ Res. 1996;78:225-230.
15. Mooradian DL, Hutsell TC, Keefer LK. Nitric oxide (NO) donor molecules: effects of NO release rate on vascular smooth muscle cell proliferation in vitro. J Cardiovasc Pharmacol. 1995;25:674-678.
16. Sharma RV, Tan E, Fang S, Gurjar MV, Bhalla RC. NOS gene transfer inhibits expression of cell cycle regulatory molecules in vascular smooth muscle cells. Am J Physiol. 1999;276(Heart Circulatory Physiology 45): H1450-H1459.
17. Von der Leyden HE, Gibbons GH, Morishita R, Lewis NP, Zhang L, Nakajima M, Kaneda Y, Cooke JP, Dzau VJ. Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. Proc Natl Acad Sci U S A. 1995;92:1137-1141.
18. Fang S, Sharma RV, Bhalla RC. Enhanced recovery of injury-caused down-regulation of paxillin protein by eNOS gene expression in rat carotid artery: a mechanism of NO inhibition of intimal hyperplasia. Arterioscler Thromb. 1999;19:147-152.
19. Bhalla RC, Sharma RV. Induction of c-fos and elastin gene in response to mechanical vascular smooth muscle cells. J Vasc Med Biol. 1993;4:130-137.
20. Bhalla RC, Toth KF, Bhatty RA, Thompson LP, Sharma RV. Estrogen treatment attenuates proliferation and agonist-induced calcium responses in cultured coronary artery smooth muscle cells. Am J Physiol. 1997;272:H1996-H2003.
21. Nishida K, Harrison DG, Navas JP, Fisher AA, Dockery SP, Uematsu M, Nerem RM, Alexander RW, Murphy TJ. Molecular cloning and characterization of the constitutive bovine aortic endothelial cell nitric oxide synthase. J Clin Invest. 1992;90:2092-2096.
22. Fang S, Sharma RV, Bhalla RC. Endothelial nitric oxide synthase gene transfer inhibits platelet-derived growth factor-BB stimulated focal adhesion kinases and paxillin phosphorylation in vascular smooth muscle cells. Biochem Biophys Res Commun. 1997;236:706-711.
23. Sharma RV, Fang S, Bhalla RC. Factors influencing adenovirus-mediated gene transfer to endothelial and vascular smooth muscle cells in vivo and in vitro. In: Pandalai SG, ed. Recent Research Developments in Molecular Biology. Trivandrum, India: Research Sinpost; 1997:41-50.
24. Oboshi H, Chu Y, Rios CD, Feraci FM, Davidson BL, Heistad DD. Altered vascular function after adenovirus-mediated overexpression of endothelial nitric oxide synthase. Am J Physiol. 1997;273:H265-H270.
25. Bhalla RC, Toth KF, Tan E, Mathias E, Sharma RV. Vascular effects of metformin: possible mechanisms for its antihypertensive action in the spontaneously hypertensive rat. Am J Hypertens. 1996;9:570-576.
26. Dubey RK, Jackson EK, Luschar TF. Nitric oxide inhibits angiotensin II-induced migration of rat aortic smooth muscle cells: role of cyclic nucleotides and angiotensin 1 receptors. J Clin Invest. 1995;96:141-149.
27. Sharma RV, Bhalla RC. PDGF-induced mitogenic signaling is not mediated through protein kinase C and c-fos pathway in VSM cells. Am J Physiol. 1993;264:C71-C79.
28. Lamas S, Marsden PA, Li GK, Tempst P, Michel T. Endothelial nitric oxide synthase: molecular cloning and characterization of a distinct constitutive enzyme isoform. Proc Natl Acad Sci U S A. 1992;89:6348-6352.
29. Kleiner DE, Stetler-Stevenson WG. Quantitative zymography: detection of picogram quantities of gelatinases. Anal Biochem. 1994;218:325-329.
30. Dixon BS, Sharma RV, Dennis MJ. The bradykinin B2 receptor is a delayed early response gene for platelet-derived growth factor in arterial smooth muscle cells. J Biol Chem. 1996;271:13324-13332.
31. Yu AE, Hewitt RE, Kleiner DE, Stetler-Stevenson WG. Molecular regulation of cellular invasion: role of gelatinase A and TIMP-2. Biochem Cell Biol. 1996;74:823-831.
32. Howard EW, Bullen EC, Banda MJ. Preferential inhibition of 72- and 92-kDa gelatinases by tissue inhibitor of metalloproteinases-2. J Biol Chem. 1991;266:13070-13075.
33. Will H, Atkinson SJ, Butler GS, Smith B, Murphy G. The soluble catalytic domain of membrane type-1 matrix metalloproteinase cleaves the propeptide of progelatinase A and initiates autoproteolytic activation: regulation by TIMP-2 and TIMP-3. J Biol Chem. 1996;271:17119-17123.
34. Sato H, Kinoshita T, Takino T, Nakayama K, Seiki M. Activation of a recombinant membrane type 1-metalloproteinase (Mt1-MMP) by furin and its interaction with tissue inhibitor of metalloproteinases (TIMP-2). FEBS Lett. 1996;393:101-104.
35. Majesky MW. Neointima formation after acute vascular injury: role of counter-adhesive extracellular matrix proteins. Tex Heart Inst J. 1994;21:78-85.
36. Davies MG, Hagen PO. Pathobiology of intimal hyperplasia. Br J Surg. 1994;81:1254-1269.
37. Howard EW, Bullen EC, Banda MJ. Regulation of the autoactivation of human 72-kDa progelatinase by tissue inhibitor of metalloproteinases-2. J Biol Chem. 1991;266:13064-13069.
38. Jenkins GM, Crow MT, Bilato C, Gluzband Y, Ryu WS, Li Z, Stetler-Stevenson W, Nater C, Froehlich JP, Lakatta EG, Cheng L. Increased expression of membrane-type matrix metalloproteinase and preferential localization of matrix metalloproteinase-2 to the neointima of balloon-injured rat carotid arteries. Circulation. 1998;97:82-90.
39. Dollery CM, McEwan JR, Wang M, Sang QA, Liu Y, Shi YE. TIMP-4 is regulated by vascular injury in rats. Circ Res. 1999;84:498-504.
40. Trachtman H, Futterweit S, Garg P, Reddy K, Singhal PC. Nitric oxide stimulates the activity of a 72-kDa neutral matrix metalloproteinase in cultured rat mesangial cells. Biochem Biophys Res Commun. 1996;218: 704-708.
41. Katsuyama K, Shichiri M, Marumo F, Hirata Y. NO inhibits cytokine-induced iNOS expression and NF-κB activation by interfering with phospnorylation and degradation of IκB-α. Arterioscler Thromb Vasc Biol. 1998;18: 1796-1802.
42. Rajgopalan S, Meng XP, Ramasamy S, Harrison DG, Galis ZS. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro: implications for atherosclerotic plaque stability. J Clin Invest. 1996;98:2572-2579.
43. Owens MW, Milligan SA, Jourd'heuil, Grisham MB. Effects of reactive metabolites of oxygen and nitrogen on gelatinase A activity. Am J Physiol. 1997;273:L445-L450.
44. Sharma RV, Fang S, Tan E, Bhalla RC. Lack of nitric oxide synthase gene induction by cytokines and lipopolysaccharides in coronary artery smooth muscle cells. In: Stamler JS, Gross SS, Moncada S, Higgs AE, et al, eds. The Biology of Nitric Oxide, Part 5. London: Portland Press; 1996:55.